Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial

Keyphrases

• Apixaban 100%
• Thromboprophylaxis 100%
• Patients with Cancer 100%
• Patients with Obesity 100%
• Ambulatory Patients 100%
• Confidence Interval 66%
• Body Mass Index 66%
• Hazard Ratio 50%
• Clinically Significant 50%
• Non-obese 50%
• Placebo 33%
• Chemotherapy 33%
• Bleeding 33%
• Venous Thromboembolism 33%
• Direct Oral Anticoagulants 33%
• Primary Prevention 33%
• Obese Patients 33%
• Obese Subjects 33%
• Ambulatory Cancer Patients 33%
• High Risk 16%
• Obesity 16%
• Efficacy Outcomes 16%
• Intermediate Risk 16%
• Major Bleeding 16%
• Hemoglobin 16%
• Placebo-controlled 16%
• Creatinine Clearance 16%
• Safety Outcomes 16%
• Venous Thromboembolism Prevention 16%
• Non-majors 16%
• Cancer Prevention 16%
• ECOG Performance Status 16%
• Low Platelet Count 16%
• Trial Population 16%
• Cancer-associated Venous Thromboembolism 16%

Medicine and Dentistry

• Thromboprophylaxis 100%
• Patient with Obesity 100%
• Apixaban 100%
• Body Mass Index 66%
• Venous Thromboembolism 66%
• Malignant Neoplasm 50%
• Placebo 50%
• Hazard Ratio 50%
• Primary Prevention 33%
• Major Bleeding 33%
• Direct Oral Anticoagulant 33%
• Bleeding 16%
• Post-Hoc Analysis 16%
• Creatinine Clearance 16%
• Electrocorticography 16%
• Low Platelet Count 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Apixaban 100%
• Venous Thromboembolism 66%
• Placebo 50%
• Bleeding 50%
• Chemotherapy 33%
• Direct Oral Anticoagulant 33%
• Creatinine 16%